WRF Capital β Full Portfolio
14 tracked investments Β· listed companies and verified rows first
2Morrow provides evidence-based digital wellness programs delivered through a smartphone and web app, using Acceptance and Commitment Therapy principles to help people quit tobacco, manage stress, and change health behaviors.
Digital HealthMental HealthWellness & FitnessKirkland, US
Jo Masterson(Executive Officer, Director)inBrandon Masterson(Executive Officer)in
BoardJohn Koster(Director)Eric Larsen(Director)in
Co-investorsPortland Seed FundAlliance of Angels
Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.
AI & Machine LearningBiotechDeep TechSeattle, US
Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)inHector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)in
Co-investorsCreative Destruction Lab (CDL)Argonautic VenturesColumbus Venture PartnersPack Ventures
Seattle, US
JACOB O. WOBBROCK(Executive Officer)inWILLIAM T. COLLERAN(Executive Officer, Director)ANDREW KO(Executive Officer)
BoardWILLIAM MCALEER(Director)inMARK UPSON(Director)MICHAEL FRIDGEN(Director)
Co-investorsCowles VenturesThe W FundVoyager Capital
BiotechSeattle, US
Rahul Shendure(Executive Officer, Director, Promoter)inMatthew Snyder(Director)
Co-investorsThe W Fund
Automates complex call center operations; acquired by Sagility Health.
Co-investorsAllen Institute for AI (AI2) IncubatorFlare Capital PartnersAI GrantRadical Ventures
Fred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
BiotechHealthtechMedical DevicesSeattle, US
Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays.
BiotechDeep TechNew MaterialsSeattle, US
Ron Myers(Executive Officer, Director)
BoardSteven Gillis(Director)Charles P. Waite(Director)Martin Simonetti(Director)Stewart Parker(Director)David Urdal(Director)
Co-investorsThe W FundAlliance of Angels
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSARCH Venture Partners
Biopharma company developing non-immunosuppressive drugs for autoimmune diseases.
James Posada, Ph.D.(Founder)in
Co-investorsNew Science VenturesEaston Capital
University of Washington is a public research institution offering undergraduate, graduate, and professional education across multiple campuses and disciplines including engineering, computer science, business, medicine, law, and environmental studies.
EdTechSeattle, US
Co-investorsShumo Chu
Washington State University is a public research institution operating six campuses across Washington state and online, offering academic programs in fields including health sciences, STEM, business, engineering, and social sciences.
EdTechPullman, US
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.